Diabetes

June 12, 2018

Carbon monoxide therapy for TIIDM and obesity-associated metabolic deficits: COR-M2(CO releasing molecule-2) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 12/June/2018, 9.31 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]
June 12, 2018

Treating blood sugar disease with low-calorie sweeteners: Xylitol-based therapy for diabetes (TIIDM): Xylitol , a low-calorie sweetener isolated from natural products, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 12/June/2018, 9.23 pm

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, […]
June 9, 2018

Treating blood sugar disease with low-calorie sweeteners: D-Allulose-based therapy for diabetes (TIIDM): D-Allulose/D-Psicose, a low-calorie sweetener isolated from natural products, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 9/June/2018, 10.32 pm

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, […]
June 7, 2018

Interleukin-based therapy for body weight control, energy homeostasis and TIIDM: Interleukin-2(IL-2) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 7/June/2018, 6.38 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]